恒瑞医药：获得美国FDA孤儿药资格认定

Core Viewpoint - Heng Rui Medicine (600276) has received orphan drug designation from the U.S. FDA for its product, injection of Rukang Qutuzumab combined with Adebeli monoclonal antibody and chemotherapy for the treatment of gastric cancer or gastroesophageal junction adenocarcinoma, which will provide opportunities for policy support in product development, registration, and commercialization in the U.S. [1] Group 1 - The product received orphan drug designation from the U.S. FDA [1] - The indication is for gastric cancer or gastroesophageal junction adenocarcinoma [1] - The designation allows for potential policy support in research, registration, and commercialization [1]